AxoGen logo
AxoGen
AXGN | NASDAQ
Chart Builder DCF Calculator
$55.38
-$0.55 (-0.98%)
At close: Nov 16, 2026, 4:00 PM ET
$55.10
-$0.28 (-0.51%)
After-hours: Nov 16, 2026, 7:44 PM ET

AxoGen Company Profile

Company profile explained

Company Profile

AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.

Key Executives

Name Position
Michael D. Dale President, Chief Executive Officer & Director
Jens Schroeder Kemp Chief Marketing Officer
Lindsey Hartley Chief Financial Officer
Craig A. Swandal Senior Vice President of Operations
Doris Quackenbush Chief Revenue Officer
Erick DeVinney Chief Scientific Officer
Harold D. Tamayo Vice President of Finance & Investor Relations
Ivica Ducic Chief Medical Officer
Marc A. Began Executive VP, General Counsel, Secretary & Chief Compliance Officer
Rick Ditto Vice President of Global Health Economics, Reimbursement & Policy

Latest SEC Filings

Date Type Title
Oct 28, 2026 10-Q Quarterly Report
Oct 28, 2026 8-K Current Report
Oct 02, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 01, 2026 8-K Current Report
Sep 10, 2026 424B5 Filing
Sep 10, 2026 8-K/A [Amend] Current Report
Sep 10, 2026 8-K Current Report
Sep 04, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 12, 2026 4 Filing
View All SEC Filings ➞
AxoGen
AxoGen logo
Country United States
IPO Date Dec 17, 1986
Industry Medical - Devices
Sector Healthcare
Employees 622
CEO Michael D. Dale

Contact Details

13631 Progress Boulevard Alachua, Florida 32615 United States

Stock Details

Ticker Symbol AXGN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000805928
CUSIP Number 05463X106
ISIN Number US05463X1063
SIC Code 3845

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.